Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)
Eli Lilly Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) decreased by 27.3% to $5.28B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 70.8%, from $3.09B to $5.28B. Over 5 years (FY 2020 to FY 2025), Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) shows an upward trend with a 14.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests improved liquidity and capacity for investment or debt repayment, while a decrease may indicate aggressive capital allocation or operational cash burn.
Detailed definition
This represents the total liquidity available to the company, including cash, cash equivalents, and restricted cash bala...
Peer comparison
Consumer staples companies typically maintain moderate cash buffers to manage working capital and dividend obligations.
cash_and_equivalents_total_inclusiveHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.22B | $3.79B | $3.82B | $2.46B | $2.62B | $2.62B | $2.07B | $3.55B | $2.69B | $2.38B | $2.82B | $2.46B | $3.22B | $3.37B | $3.27B | $3.09B | $3.38B | $9.79B | $7.27B | $5.28B |
| QoQ Change | — | +17.6% | +0.8% | -35.6% | +6.7% | -0.2% | -21.0% | +71.5% | -24.0% | -11.6% | +18.4% | -12.7% | +31.0% | +4.5% | -3.0% | -5.4% | +9.1% | +190.1% | -25.8% | -27.3% |
| YoY Change | — | — | — | — | -18.5% | -30.9% | -45.9% | +44.2% | +2.7% | -9.0% | +36.4% | -30.6% | +19.6% | +41.5% | +15.9% | +25.7% | +4.7% | +190.6% | +122.4% | +70.8% |
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at Other Companies
Frequently Asked Questions
- What is Eli Lilly's total cash, cash equivalents, and restricted cash (inclusive)?
- Eli Lilly (LLY) reported total cash, cash equivalents, and restricted cash (inclusive) of $5.28B in Q1 2026.
- How has Eli Lilly's total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
- Eli Lilly's total cash, cash equivalents, and restricted cash (inclusive) increased by 70.8% year-over-year, from $3.09B to $5.28B.
- What is the long-term trend for Eli Lilly's total cash, cash equivalents, and restricted cash (inclusive)?
- Over 5 years (2020 to 2025), Eli Lilly's total cash, cash equivalents, and restricted cash (inclusive) has grown at a 14.7% compound annual growth rate (CAGR), from $3.66B to $7.27B.
- What does total cash, cash equivalents, and restricted cash (inclusive) mean?
- The total amount of cash and highly liquid assets the company holds.